AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36099670 — intervention group
Group type: COMPARATOR
Intervention: docetaxel plus prednisone
Number of subjects: 148
Study 33821797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 49
Study 33821797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 32460885 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Speech and Language Therapy (SLT)
Number of subjects: 546
Study 32460885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT LOUD®)
Number of subjects: 546
Study 32460885 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 546
Study 32460885 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS SLT
Number of subjects: 546
Study 32460885 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD®
Number of subjects: 546
Study 34846593 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E) - chest drain removal at 5 ml/kg daily output
Number of subjects: 80
Study 34846593 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - chest drain removal at less than 250 ml/day
Number of subjects: 80
Study 34846593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 33225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmenting with aripiprazole (A-ARI)
Number of subjects: 1522
Study 33225492 — intervention group
Group type: COMPARATOR
Intervention: Switching to bupropion-SR (S-BUP)
Number of subjects: 1522
Study 33225492 — intervention group
Group type: COMPARATOR
Intervention: Combining with bupropion-SR (C-BUP)
Number of subjects: 1522
Study 33225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (all groups)
Number of subjects: 1522
Study 36471311 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA) for integrating HIV testing into FP services
Number of subjects: 36086
Study 36471311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministry of Health-supported intervention scenario
Number of subjects: 36086
Study 33271536 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning program (90-min sessions weekly for 24 weeks)
Number of subjects: 60
Study 33271536 — intervention group
Group type: COMPARATOR
Intervention: Control group (90-min didactic teaching method)
Number of subjects: 60
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (low dose, 1 × 10^5 TCID50)
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (high dose, 1 × 10^6 TCID50)
Number of subjects: 90
Study 35045362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (two injections)
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (low dose, two injections)
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (high dose, two injections)
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: V591
Number of subjects: 90
Study 35045362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing anti-measles immunity
Number of subjects: 90
Study 32704178 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and adipose tissue content assessment
Number of subjects: 0
Study 32704178 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive diagnostic methods for mapping foot load distribution
Number of subjects: 0
Study 36420365 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and Kinetic Treatment with Rehabilitation (FAKTR) combined with cryotherapy
Number of subjects: 40
Study 36420365 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 40
Study 32247315 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (BH) spray
Number of subjects: 142
Study 32247315 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline lubrication without BH spray)
Number of subjects: 142
Study 33107977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue level implants with a partially smooth collar in thin phenotype group (n=13)
Number of subjects: 30
Study 33107977 — intervention group
Group type: COMPARATOR
Intervention: Tissue level implants with a partially smooth collar in thick phenotype group (n=13)
Number of subjects: 30
Study 36195338 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS006 5 mg once daily
Number of subjects: 9
Study 36195338 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS006 15 mg once daily
Number of subjects: 9
Study 36195338 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS006 20-80 mg twice a day
Number of subjects: 9
Study 36195338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 36195338 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS006 (various doses)
Number of subjects: 9
Study 36195338 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS006
Number of subjects: 9
Study 34751928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront (TAAR1 agonist)
Number of subjects: 245
Study 34751928 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245
Study 34751928 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245
Study 34751928 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (Dopamine D2 receptor-based antipsychotic)
Number of subjects: 245
Study 34751928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 32844196 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa monotherapy
Number of subjects: 30
Study 32844196 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 30
Study 32844196 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 30
Study 35317736 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation + Virtual Reality (AO + VR)
Number of subjects: 0
Study 35317736 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (Observation of naturalistic scenes + Virtual Reality) (CO + VR)
Number of subjects: 0
Study 34479958 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (1-84)
Number of subjects: 0
Study 34479958 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 34905513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ob-NFG-NGT
Number of subjects: 5
Study 34905513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ob-NFG-IGT
Number of subjects: 5
Study 34905513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ob-IFG-IGT
Number of subjects: 5
Study 34905513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ob-T2D
Number of subjects: 5
Study 34905513 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin clearance
Number of subjects: 5
Study 35041000 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multimodality imaging-guided LV lead placement
Number of subjects: 182
Study 35041000 — intervention group
Group type: COMPARATOR
Intervention: Routine fluoroscopic approach (Control)
Number of subjects: 182
Study 35041000 — intervention group
Group type: EXPERIMENTAL
Intervention: IED ≥100 ms
Number of subjects: 182
Study 32054536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg) alongside standard TB treatment
Number of subjects: 0
Study 32054536 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rifampicin alongside standard TB treatment
Number of subjects: 0
Study 35981598 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 51
Study 35981598 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 51
Study 34105866 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg capsule twice daily for 3 months
Number of subjects: 92
Study 34105866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 34105866 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 92
Study 32873323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention involving brief motivation/support by practice nurses
Number of subjects: 28
Study 32873323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (healthy lifestyle leaflet)
Number of subjects: 28
Study 36255560 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy 1 perspective
Number of subjects: 402
Study 36255560 — intervention group
Group type: COMPARATOR
Intervention: Proxy 2 (substitute) perspective
Number of subjects: 402
Study 33185376 — intervention group
Group type: COMPARATOR
Intervention: 30 mL 0.5% bupivacaine at 23°C
Number of subjects: 90
Study 33185376 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% bupivacaine warmed to 37°C
Number of subjects: 90
Study 35819542 — intervention group
Group type: EXPERIMENTAL
Intervention: National Career Coach Program (NCCP)
Number of subjects: 208
Study 35819542 — intervention group
Group type: COMPARATOR
Intervention: Local Community Resources (LCR)
Number of subjects: 208
Study 34846050 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinematic chain exercises with eccentric and strength exercises
Number of subjects: 84
Study 34846050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 35803088 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg lavender flowers capsules, taken three times daily for 60 days
Number of subjects: 48
Study 35803088 — intervention group
Group type: COMPARATOR
Intervention: 600mg cornstarch capsules, taken three times daily for 60 days
Number of subjects: 48
Study 34347865 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to Quit digital therapeutic
Number of subjects: 62
Study 34347865 — intervention group
Group type: COMPARATOR
Intervention: NCI QuitGuide digital therapeutic
Number of subjects: 62
Study 34724246 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Comfort System (PCS)
Number of subjects: 18
Study 34724246 — intervention group
Group type: COMPARATOR
Intervention: Control (no PCS)
Number of subjects: 18
Study 33929284 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscal repair
Number of subjects: 150
Study 33929284 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 150
Study 34396615 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 70
Study 34396615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 32357926 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (7-week partnership-based and needs-tailored SMS intervention via telephone counseling)
Number of subjects: 94
Study 32357926 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 94
Study 32357926 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study 35029869 — intervention group
Group type: EXPERIMENTAL
Intervention: Early NMBA
Number of subjects: 1182
Study 35029869 — intervention group
Group type: COMPARATOR
Intervention: No early NMBA
Number of subjects: 1182
Study 32697197 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with health professional support to increase nebulizer adherence, including electronic monitoring and tailored website support.
Number of subjects: 14
Study 32697197 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with health professional support to increase nebulizer adherence, tailored to individuals.
Number of subjects: 14
Study 32697197 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intervention delivered through an app accessed via mobile phones.
Number of subjects: 14
Study 36384398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver combined with controlled low central venous pressure (Group 20)
Number of subjects: 151
Study 36384398 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 15)
Number of subjects: 151
Study 34082176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% dietary Cl
Number of subjects: 360
Study 34082176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.21% dietary Cl
Number of subjects: 360
Study 34082176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.21% and 0.15% dietary Cl
Number of subjects: 360
Study 34082176 — intervention group
Group type: COMPARATOR
Intervention: Na2SO4 and NaHCO3
Number of subjects: 360
Study 32773737 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) and postoperative intravenous analgesia (Group A)
Number of subjects: 0
Study 32773737 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) and postoperative epidural analgesia (Group B)
Number of subjects: 0
Study 32773737 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) combined with thoracic epidural anesthesia (TEA) and postoperative intravenous analgesia (Group C)
Number of subjects: 0
Study 32773737 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) combined with TEA and postoperative epidural analgesia (Group D)
Number of subjects: 0
Study 34128083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg bid)
Number of subjects: 5022
Study 34128083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study 34128083 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset AF
Number of subjects: 5022
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine 150 mg, 300 mg, 450 mg (single daily doses for 3 days)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine 600 mg (multiple daily doses for 6 days)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine (various doses)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine 300 mg to 600 mg (single dose)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine 600 mg (once daily for 5 days)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine (all doses)
Number of subjects: 0
Study 36368677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomyosamine (elimination pathway)
Number of subjects: 0
Study 33958552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (ICUs 3 and 4; educational intervention with no monitoring visits)
Number of subjects: 117
Study 33958552 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICU 5; receiving no intervention)
Number of subjects: 117
Study 33958552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (ICUs 1 and 2; full intervention with monitoring visits)
Number of subjects: 117
Study 35954509 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 72
Study 35954509 — intervention group
Group type: COMPARATOR
Intervention: Brachial Plexus Block (BPB)
Number of subjects: 72
Study 33491389 — intervention group
Group type: EXPERIMENTAL
Intervention: PerioTabs (NitrAdine-based gingiva brushing solution) for 10 days
Number of subjects: 49
Study 33491389 — intervention group
Group type: COMPARATOR
Intervention: Any toothpaste (control group)
Number of subjects: 49
Study 32079835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic tattoos (reported by 17% of cases and 26% of controls)
Number of subjects: 369
Study 32079835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattoo colors (specifically yellow and green)
Number of subjects: 369
Study 35152314 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model based on FS-T1WI and FS-T2WI sequences
Number of subjects: 100
Study 35152314 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model based on FS-T1WI and FS-T2WI sequences
Number of subjects: 100
Study 35152314 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model in training group
Number of subjects: 100
Study 35152314 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model in test group
Number of subjects: 100
Study 34006044 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care procalcitonin (PCT) test with standard sepsis parameter monitoring
Number of subjects: 100
Study 34006044 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring only (C-reactive protein, total white count, temperature, tracheal aspirate culture)
Number of subjects: 100
Study 35788146 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser radiation (diode laser 808 nm)
Number of subjects: 38
Study 35788146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 38
Study 33439864 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit condition (children told the sorting rules)
Number of subjects: 137
Study 33439864 — intervention group
Group type: COMPARATOR
Intervention: Implicit condition (children given feedback to formulate the rules)
Number of subjects: 137
Study 33439864 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit condition
Number of subjects: 137
Study 33439864 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 137
Study 35076302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavlik harness treatment
Number of subjects: 104
Study 35076302 — intervention group
Group type: COMPARATOR
Intervention: Active observation
Number of subjects: 104
Study 32902207 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks exercise program (resistance training, balance exercise, aerobic exercise)
Number of subjects: 96
Study 32902207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 96
Study 32902207 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks exercise program
Number of subjects: 96
Study 35377947 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg once daily until disease progression/unacceptable toxicity (n = 136)
Number of subjects: 269
Study 35377947 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil 0.5-0.8 mg/kg ≤12 cycles (n = 133)
Number of subjects: 269
Study 35377947 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib
Number of subjects: 269
Study 33991471 — intervention group
Group type: EXPERIMENTAL
Intervention: RE bout with WBV
Number of subjects: 20
Study 33991471 — intervention group
Group type: COMPARATOR
Intervention: RE bout
Number of subjects: 20
Study 32558199 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept maintenance therapy
Number of subjects: 69
Study 32558199 — intervention group
Group type: COMPARATOR
Intervention: Control group with rabbit antithymocyte globulin (rATG) induction, rapid steroid taper, and maintenance mycophenolate and tacrolimus
Number of subjects: 69
Study 36328822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Number of subjects: 80
Study 36328822 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 33894947 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management through low-intensity psychological intervention
Number of subjects: 30
Study 32680912 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved biomass stoves vented with a chimney (Trial 1)
Number of subjects: 0
Study 32680912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vented biomass stoves (Trial 2)
Number of subjects: 0
Study 32680912 — intervention group
Group type: COMPARATOR
Intervention: Liquid petroleum gas (LPG) stoves (Trial 2)
Number of subjects: 0
Study 34501680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief multimedia animated video about ACL injury and prevention
Number of subjects: 0
Study 34501680 — intervention group
Group type: COMPARATOR
Intervention: Commonly accessed, text-based web resource about ACL injury and prevention
Number of subjects: 0
Study 34501680 — intervention group
Group type: COMPARATOR
Intervention: Brief multimedia video about concussions
Number of subjects: 0
Study 33253497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 820
Study 33253497 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (TCZ) combined with methotrexate (TCZ+MTX)
Number of subjects: 820
Study 36251465 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 36251465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 32891161 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of temporary suspension in clinical trials
Number of subjects: 0
Study 35101098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium bromide for 48 hours
Number of subjects: 0
Study 35101098 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 hours
Number of subjects: 0
Study 32809900 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing painful images
Number of subjects: 21
Study 32809900 — intervention group
Group type: COMPARATOR
Intervention: Viewing pleasant images
Number of subjects: 21
Study 32809900 — intervention group
Group type: COMPARATOR
Intervention: Viewing neutral images
Number of subjects: 21
Study 35379247 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform and structured telephone support
Number of subjects: 86
Study 35379247 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform
Number of subjects: 86
Study 35379247 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform direct messaging
Number of subjects: 86
Study 35379247 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-dial telephone contact
Number of subjects: 86
Study 32152018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Algorithm for Singaporeans with Type 2 Diabetes (FAST)
Number of subjects: 97
Study 32152018 — intervention group
Group type: COMPARATOR
Intervention: Usual care without FAST
Number of subjects: 97
Study 33960508 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch (NT) technique
Number of subjects: 100
Study 33960508 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 100
Study 35303932 — intervention group
Group type: EXPERIMENTAL
Intervention: New membrane obturator prosthesis
Number of subjects: 14